RE:RE:RE:Blood vessel damageMHI Phase 1 AV study go ahead must have been based on their previous work with University of Minnesota on exercise induced inflammation as well as Ceapro's own in vitro studies.
Without results from the Angiogenesis study which was to look at BG and AV, what input did the Angiogenesis Foundation work have in the design of the Phase 1 AV study to be conducted by MHI? The public hasn't been privy to any preliminary or interim results.
prophetoffactz wrote: The Angiogenesis Foundation was studying avenanthramide. CZO's avenanthramide clinical trial is expected to get the 'green light' from Health Canada imminently. Gilles has previously said he hoped to include a trial arm for COVID heart inflammation. Perhaps COVID blood vessel damage could also be studied. Blood vessel damage is also important in cardiovascular disease which has been the principle target for the avenanthramide trial.
Ciao wrote: Over a year of preclinical in vivo studies by the Angiogenesis Foundation, so should we expect Phase 1 studies to begin sometime in 2023?
"the Angiogenesis Foundation will be conducted to characterize the in vivo bioactivity of Ceapro’s oat-derived bioactive products, beta glucan and avenanthramides, on angiogenesis, blood vessels repair, wound healing and tissue regeneration."
In parallel the YBG animal study results from McMaster will either lead to further studies with loaded YBG and or Phase 1 in 2023 as well.